Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Cancer Chemoprevention: Progress and Promise

Lippman, S. M., Lee, J. J., Sabichi, A. L. · 1998 · JNCI Journal of the National Cancer Institute

Abstract

In the relatively brief history of cancer chemoprevention, hundreds of chemoprevention studies have been reported. The vast majority were uncontrolled studies that were designed and reported in a nonrigorous fashion, which perhaps resulted largely from the zealousness of early chemoprevention researchers to nurture growth of an exciting novel approach through its infancy. Nevertheless, limitations characterizing many of these trials have tended to cloud chemoprevention's record of progress and promise. This tendency overlooks the solid cohort of definitive randomized trials that have successfully addressed many important clinical questions. What distinguishes chemotherapy from chemoprevention? The simplest answer is that the former involves agents that treat cancer, and the latter involves agents that prevent cancer by either preventing or treating premalignant lesions. This distinction, however, is blurred by several recent results. Some agents, such as retinoids and tamoxifen, can both prevent and treat cancer. Several newer agents, including angiogenesis inhibitors and ras inhibitors, also show activity and promise in both preinvasive and invasive carcinogenesis. The distinction between premalignant and malignant lesions also is becoming blurred by new findings in molecular biology. For example, clonal expansion now is seen in preinvasive stages as well as in invasive stages of carcinogenesis. Furthermore, it is not always clear whether an agent is treating subclinical (e.g., microscopic) cancer or is treating premalignant lesions and thus preventing progression to cancer. Agents for which this issue has been raised are retinoids in the prevention of second primary head and neck cancers and tamoxifen in the prevention of breast cancer in the Breast Cancer Prevention Trial (BCPT). Every trial that we discuss in this commentary involves specific natural or synthetic chemical agents used to reverse, suppress, or prevent carcinogenic progression to invasive cancer. None of the studies involves a nutritional intervention with foods ingested in a normal diet. This points out the important distinction between the field of cancer chemoprevention and the field of diet and cancer (1) . The natural agent β-carotene is an example of a compound that can be the subject of both fields. Ingestion of fruits and vegetables high in β-carotene can be a dietary intervention; however, when taken as an extracted and purified natural compound, β-carotene qualifies as a chemoprevention agent. There have been more than 60 randomized chemoprevention trials reported in the English language literature ( 1 – 3 ); nine of these trials, we believe, qualify as definitive trials. As presented in Table 1 and Fig. 1 , these nine trials involved 15 primary interventions or end points, which were subjected to rigorous hypothesis testing ( 4 – 14 ). What is a “definitive” chemoprevention trial? The criteria used for selecting definitive trials discussed in this commentary include the following elements of rigorous study design: 1) primary end point of cancer incidence; 2) twosided hypothesis testing; 3) randomization with placebo control versus interventions; and 4) large scale (n ⩾ 1000), with the definitive sample size and duration based on anticipated event rates in the intervention arm (treatment effect) and placebo arm. Every definitive trial included in this commentary had a duration greater than 3.5 years and was supported by the National Cancer Institute. These design elements contribute to the ability of a trial to achieve either a statistically significant definitive result (positive/protective or negative/harmful) or a definitive null result (negative/neutral) that is truly informative (either of which is necessary for making public policy recommendations) (15) . Two of the 15 definitive reported to from statistically significant are from was statistically significant between and placebo Two are from statistically significant the arm was statistically than the placebo arm with to cancer and ( Table 1 and Fig. 1 ). Several when the record of definitive chemoprevention in Fig. 1 . by these studies in primary (e.g., agents, and of the including both of the statistically significant involved interventions with and are the definitive trials in Fig. 1 . The statistically significant were in the recent trials, both reported in the The recent to the of definitive studies was the with statistically significant that tamoxifen the of breast cancer . and for 15 from definitive cancer chemoprevention trials. used to are in more in Table 1 the to an with the in Table 1 and The is a trial that has a chemoprevention agent to the of the of As agent has been by the and for in and and National Cancer for tamoxifen are tamoxifen for the of breast is perhaps a of high of breast cancer. of this including the duration of tamoxifen and the of for tamoxifen are discussed in definitive chemoprevention not or of also an of of cancer prevention and carcinogen

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/90.20.1514

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 194

Metadata

Authors
Lippman, S. M., Lee, J. J., & Sabichi, A. L.
Venue
JNCI Journal of the National Cancer Institute
Published
1998-10-21
Volume
90
Issue
20
Pages
1514-1528
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W1994331461
Cited by
194
References
11
FWCI
9.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer Chemoprevention: Progress and Promise. https://app.cochat.ai/papers/10.1093/jnci/90.20.1514
The paper
Lippman, S. M., Lee, J. J., & Sabichi, A. L. (1998). Cancer Chemoprevention: Progress and Promise. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/90.20.1514

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.